Sanofi-Aventis Takes Rights to Metabolex's Diabetes Compound
This article was originally published in The Pink Sheet Daily
Executive Summary
As it continues to diversify away from its juggernaut Lantus, Sanofi takes a chance on a potential first-in-class drug not yet through Phase II.
You may also be interested in...
Thinking Long-Term, Novo Ventures Finds Itself On A Hot Streak Of Quick Exits
Despite a strategy that encourages holding stakes when other firms might sell, the evergreen fund has been generating quick returns.
Thinking Long-Term, Novo Ventures Finds Itself On A Hot Streak Of Quick Exits
Despite a strategy that encourages holding stakes when other firms might sell, the evergreen fund has been generating quick returns.
Novo Ventures' Hot Streak Of Exits
The evergreen fund is on a hot streak thanks to a recent string of exits.